Jun 14 2005
CalbaTech announced today that its wholly owned subsidiary, LifeStem has filed a U.S. Patent Application for its Stem Cell Delivery Device. The patent is for the Device and Methods for Treatment of Necrotic Tissue using Stem Cells.
The Stem Cell Delivery Device, for which the utility patent was filed, is a system for the regeneration of cardiac muscle post myocardial infarction. This apparatus is designed for the targeted delivery of peripheral blood-derived autologous adult stem cells to diseased tissue for the purpose of regenerating healthy functional tissue. The Company believes that adult stem cells have tremendous potential to promote the regeneration of dead or diseased cardiac tissue.
"We are pleased that research continues to show that adult stem cells provide significant promise for restorative therapies," said LifeStem President Dan Fulkerson. "LifeStem is committed to its plan to continue to work with adult stem cells and to further develop our delivery of stem cells into diseased heart tissue through our proprietary system," said Mr. Fulkerson. "The Company continues to move forward expeditiously in the stem cell arena, which holds the promise of conquering some of mankind's most dreaded diseases."
Current scientific data supports the contention that stem cells hold huge promise for the treatment, cure and possible prevention of numerous diseases including heart disease and Parkinson's Disease, as well as spinal cord injuries. Recent data has indicated that if adult autologous (one's own) stem cells are reintroduced to the donor, it could provide advantages similar to embryonic stem cells without the risk of rejection.
Researchers discover how mutations disrupt protein splicing and cause disease